Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Benzinga Insights

BIZARRE: Looking into alnylam pharmaceuticals s return on capital employed - What They Never Told You

Benzinga Pro data, Alnylam Pharmaceuticals (NASDAQ:ALNY) reported Q4 sales of $258.54 million. Earnings fell to a loss of $258.46 million, resulting in a 26.38% decrease from last quarter. In Q3, Alnylam Pharmaceuticals brought in $187.63 million in sales but lost $204.51 million in earnings.

Why Is ROCE Significant?

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.